Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy

被引:88
作者
Pakker, NG
Kroon, EDMB
Roos, MTL
Otto, SA
Hall, D
Wit, FWNM
Hamann, D
van der Ende, ME
Claessen, FAP
Kauffmann, RH
Koopmans, PP
Kroon, FP
ten Napel, CHH
Sprenger, HG
Weigel, HM
Montaner, JSG
Lange, JMA
Reiss, P
Schellekens, PTA
Miedema, F
机构
[1] Univ Amsterdam, Clin & Expt Immunol Lab, Dept Clin Viroimmunol, CLB,Sanquin Blood Supply Fdn, NL-1066 CX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[4] Univ Hosp Dijkzigt, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands
[5] Free Univ Amsterdam Hosp, Dept Internal Med, Amsterdam, Netherlands
[6] Leijenburg Hosp, Dept Internal Med, The Hague, Netherlands
[7] Univ Nijmegen St Radboud Hosp, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands
[8] Univ Leiden Hosp, Dept Infect Dis, NL-2300 RC Leiden, Netherlands
[9] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands
[10] Univ Groningen Hosp, Dept Internal Med, NL-9713 EZ Groningen, Netherlands
[11] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands
[12] Univ British Columbia, St Pauls Hosp, Canadian HIV Trials Network, Vancouver, BC V5Z 1M9, Canada
[13] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[14] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands
关键词
long-term immune reconstitution; antiretroviral therapy; viral suppression;
D O I
10.1097/00002030-199902040-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Current antiretroviral treatment can induce significant and sustained virological and immunological responses in HIV-1-infected persons over at least the short- to mid-term. Objectives: In this study, long-term immune reconstitution was investigated during highly active antiretroviral therapy. Methods: Patients enrolled in the INCAS study in The Netherlands were treated for 102 weeks (range 52-144 weeks) with nevirapine (NVP) + zidovudine (ZDV) (n = 9), didanosine (ddl) + ZDV (n 10), or NVP + ddl + ZDV (n = 10). Memory and naive CD4+ and CD8+ T cells were measured using CD45RA and CD27 monoclonal antibodies (mAb), T-cell function was assayed by CD3 + CD28 mAb stimulation, and plasma HIV-1 RNA load was measured by ultra-direct assay (cut-off < 20 copies/ml). Results: Compared to both double combination regimens the triple combination regimen resulted in the most sustained increase in CD4+ T cells (change in CD4+ + 253 x 10(6) cells/l; standard error, 79 x 10(6) cells/l) and reduction of plasma HIV-1 RNA. In nine patients (31%) (ddl + ZDV, n = 2; NVP + ddl + ZDV, n = 7) plasma HIV-1 RNA levels remained below cut-off for at least 2 years. On average, these long-term virological responders demonstrated a significantly higher increase of naive and memory CD4+ T cells (P = 0.01 and 0.02, respectively) as compared with patients with a virological failure, and showed improved T-cell function and normalization of the naive: memory CD8+ T-cell ratio. However, individual virological success or failure did not predict the degree of immunological response. T-cell patterns were independent of baseline CD4+ T-cell count, T-cell Function, HIV-1 RNA load or age. Low numbers of naive CD4+ T cells at baseline resulted in modest long-term naive T-cell recovery Conclusions: Patients with prolonged undetectable plasma HIV-1 RNA levels during antiretroviral therapy do not invariably show immune restoration. Naive T-cell recovery in the setting of complete viral suppression is a gradual process, similar to that reported for immune recovery in adults after chemotherapy and bone marrow transplantation. (C) 1999 Lippincott WiiIiams & Wilkins.
引用
收藏
页码:203 / 212
页数:10
相关论文
共 37 条
[1]  
[Anonymous], 1996, Lancet, V348, P283
[2]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[3]   THE PREDICTIVE VALUE OF T-CELL FUNCTION IN-VITRO AND PRE-AIDS ZIDOVUDINE USE FOR SURVIVAL AFTER AIDS DIAGNOSIS IN A COHORT OF HOMOSEXUAL MEN IN AMSTERDAM [J].
BINDELS, PJE ;
KROL, A ;
ROOS, M ;
VEENSTRA, J ;
VANDENHOEK, JAR ;
MIEDEMA, F ;
COUTINHO, RA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :97-104
[4]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[5]   WHOLE-BLOOD LYMPHOCYTE-CULTURES [J].
BLOEMENA, E ;
ROOS, MTL ;
VANHEIJST, JLAM ;
VOSSEN, JMJJ ;
SCHELLEKENS, PTA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 122 (02) :161-167
[6]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[7]   A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients [J].
Carr, A ;
Vella, S ;
deJong, MD ;
Sorice, F ;
Imrie, A ;
Boucher, CA ;
Cooper, DA .
AIDS, 1996, 10 (06) :635-641
[8]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883
[9]   AIDS therapy - Failure isn't what it used to be ... but neither is success [J].
Cohen, J .
SCIENCE, 1998, 279 (5354) :1133-1134
[10]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571